Early treatment study
et al., medRxiv, doi:10.1101/2020.06.10.20101105 (Preprint)
A short therapeutic regimen based on hydroxych loroquine plus azithromycin for the treatment of COVID-19 in patients with non-severe disease. A strategy associated with a reduction in hospital admissions and complications.
80 moderate cases, HC Q+AZ appears to reduce serious complications and death. Moderate treated cases resulted in hospitalization at the same rate as mild untreated cases suggesting efficacy.
Please send us corrections, updates, or comments.